[{"Assets_0_Q3_USD":3703943000.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":52594000.0,"NetIncomeLoss_1_Q3_USD":-265006000.0,"NetIncomeLoss_3_Q3_USD":-329789000.0,"StockholdersEquity_0_Q3_USD":218001000.0,"EarningsPerShareBasic_1_Q3_USD":-2.03,"EarningsPerShareBasic_3_Q3_USD":-2.56,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q3_shares":130729000.0,"WeightedAverageNumberOfSharesOutstandingBasic_3_Q3_shares":128822000.0,"Ticker":"AMRX","CIK":"1723128","name":"AMNEAL PHARMACEUTICALS, INC.","OfficialName":"Amneal Pharmaceuticals Inc. Class A Common Stock","form":"10-Q","period":"20190930","fy":"2019.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"632684518.0","Country":"nan","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NYSE","SP500":"nan","filed":"20191107"}]